Omeros (OMER) Tops Q3 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/6/2026
- Stocks close lower as investors eye Mideast talks, earnings
- Trump held multiple undisclosed calls with Fed Chair Warsh, reports say
- Sandisk unveils underwhelming outlook despite AI demand surge; shares slip
- Alphabet taps bond market with sweeping 10-part offering to fuel AI ambitions
- Citi says buy the pullback in memory stocks as upcycle is still in early innings
- Salesforce president Srini Tallapragada steps down, becomes advisor
- EverCommerce names Alex Goor as new CEO, founder steps down
- Sandisk (SNDK) Tops Q4 EPS by $4.66, Offers Guidance
- Crude Inventory Rose 2.5 Million Barrels Last Week - EIA
- AMD shares slide 8% after Musk flags plans to buy Nvidia chips for SpaceX
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
- After-Hours Movers: SPCX, AMD, ANET, PINS, APPS, UPST, ZETA, BKNG, LCID, CPNG, MTCH
- After-Hours Stock Movers: PLTR, SNAP, ON, ICHR, WGS, WHR
- After-Hours Stock Movers: AAPL, AMZN, COIN, RBLX, RDDT, AXTI, FND, WU, GDDY
Omeros Corporation Reports Third Quarter 2015 Financial Results
November 9, 2015 4:10 PM ESTSEATTLE, Nov. 9, 2015 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing both small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system, today announced recent highlights and developments as well as financial results for the third quarter of 2015, which include:
Omidria® (phenylephrine and ketorolac injection) 1% / 0.3% units shipped by wholesalers ("sell-through") during Q3 increased 71% from prior quarter with no change to net revenue per vial sold from prior quarter... More